A detailed history of Stifel Financial Corp transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 29,035 shares of ESPR stock, worth $71,135. This represents 0.0% of its overall portfolio holdings.

Number of Shares
29,035
Previous 31,351 7.39%
Holding current value
$71,135
Previous $93,000 17.2%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$2.02 - $3.02 $4,678 - $6,994
-2,316 Reduced 7.39%
29,035 $77,000
Q4 2023

Feb 12, 2024

SELL
$0.73 - $3.08 $12,393 - $52,289
-16,977 Reduced 35.13%
31,351 $93,000
Q3 2023

Nov 13, 2023

SELL
$0.96 - $1.79 $55,471 - $103,431
-57,783 Reduced 54.46%
48,328 $47,000
Q2 2023

Aug 14, 2023

BUY
$1.2 - $1.76 $62,451 - $91,595
52,043 Added 96.25%
106,111 $147,000
Q1 2023

May 12, 2023

BUY
$1.46 - $7.3 $41,626 - $208,130
28,511 Added 111.56%
54,068 $85,000
Q4 2022

Feb 13, 2023

SELL
$5.09 - $8.5 $22,009 - $36,754
-4,324 Reduced 14.47%
25,557 $159,000
Q3 2022

Nov 14, 2022

SELL
$5.45 - $8.13 $38 - $56
-7 Reduced 0.02%
29,881 $200,000
Q2 2022

Aug 15, 2022

SELL
$4.77 - $6.67 $98,419 - $137,622
-20,633 Reduced 40.84%
29,888 $190,000
Q1 2022

May 13, 2022

BUY
$3.34 - $5.56 $102,491 - $170,614
30,686 Added 154.71%
50,521 $234,000
Q4 2021

Feb 14, 2022

SELL
$4.81 - $11.92 $187 - $464
-39 Reduced 0.2%
19,835 $99,000
Q3 2021

Nov 15, 2021

BUY
$11.34 - $21.37 $44,634 - $84,112
3,936 Added 24.7%
19,874 $239,000
Q2 2021

Aug 13, 2021

SELL
$19.4 - $28.71 $205,271 - $303,780
-10,581 Reduced 39.9%
15,938 $337,000
Q1 2021

May 14, 2021

BUY
$25.12 - $36.89 $32,103 - $47,145
1,278 Added 5.06%
26,519 $744,000
Q4 2020

Feb 12, 2021

SELL
$24.2 - $35.76 $278,130 - $410,989
-11,493 Reduced 31.29%
25,241 $657,000
Q3 2020

Nov 16, 2020

SELL
$31.18 - $52.71 $28,342 - $47,913
-909 Reduced 2.41%
36,734 $1.37 Million
Q2 2020

Aug 14, 2020

BUY
$30.04 - $51.31 $166,661 - $284,667
5,548 Added 17.29%
37,643 $1.93 Million
Q1 2020

May 14, 2020

SELL
$27.44 - $73.84 $96,122 - $258,661
-3,503 Reduced 9.84%
32,095 $1.01 Million
Q4 2019

Feb 13, 2020

BUY
$35.4 - $59.82 $244,649 - $413,416
6,911 Added 24.09%
35,598 $2.12 Million
Q3 2019

Nov 13, 2019

BUY
$34.47 - $47.53 $125,126 - $172,533
3,630 Added 14.49%
28,687 $1.05 Million
Q2 2019

Aug 14, 2019

BUY
$40.1 - $52.33 $123,909 - $161,699
3,090 Added 14.07%
25,057 $1.16 Million
Q1 2019

May 14, 2019

BUY
$40.11 - $53.57 $1,604 - $2,142
40 Added 0.18%
21,967 $878,000
Q4 2018

Feb 13, 2019

BUY
$36.99 - $59.11 $3,292 - $5,260
89 Added 0.41%
21,927 $1.02 Million
Q3 2018

Nov 13, 2018

BUY
$40.74 - $51.41 $276,420 - $348,816
6,785 Added 45.07%
21,838 $966,000
Q2 2018

Aug 14, 2018

BUY
$36.2 - $76.4 $94,554 - $199,556
2,612 Added 21.0%
15,053 $593,000
Q1 2018

May 11, 2018

BUY
$65.94 - $80.76 $117,505 - $143,914
1,782 Added 16.72%
12,441 $895,000
Q4 2017

Feb 14, 2018

BUY
$43.47 - $67.43 $68,117 - $105,662
1,567 Added 17.23%
10,659 $702,000
Q3 2017

Nov 13, 2017

BUY
$43.8 - $52.77 $398,229 - $479,784
9,092
9,092 $0

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $163M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.